JP2023502843A - 癌を処置するために使用されるｉｌ－１５融合ペプチド - Google Patents

癌を処置するために使用されるｉｌ－１５融合ペプチド Download PDF

Info

Publication number
JP2023502843A
JP2023502843A JP2022519139A JP2022519139A JP2023502843A JP 2023502843 A JP2023502843 A JP 2023502843A JP 2022519139 A JP2022519139 A JP 2022519139A JP 2022519139 A JP2022519139 A JP 2022519139A JP 2023502843 A JP2023502843 A JP 2023502843A
Authority
JP
Japan
Prior art keywords
seq
fusion polypeptide
sequence
polypeptide
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502843A5 (enExample
Inventor
ガルスティアン，クリスティーン
スミス，リチャード
スモラレク，ドロタ
パパエバンゲロ，エフシミーア
ダスグプタ，プローカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prostate Cancer Research Centre
Kings College London
Original Assignee
Prostate Cancer Research Centre
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prostate Cancer Research Centre, Kings College London filed Critical Prostate Cancer Research Centre
Publication of JP2023502843A publication Critical patent/JP2023502843A/ja
Publication of JP2023502843A5 publication Critical patent/JP2023502843A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022519139A 2019-09-25 2020-09-25 癌を処置するために使用されるｉｌ－１５融合ペプチド Pending JP2023502843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1913804.9 2019-09-25
GB201913804A GB201913804D0 (en) 2019-09-25 2019-09-25 Fusion polypeptides
PCT/GB2020/052328 WO2021058973A1 (en) 2019-09-25 2020-09-25 Il-15 fusion peptides used to treat cancer

Publications (2)

Publication Number Publication Date
JP2023502843A true JP2023502843A (ja) 2023-01-26
JP2023502843A5 JP2023502843A5 (enExample) 2023-09-28

Family

ID=68425465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519139A Pending JP2023502843A (ja) 2019-09-25 2020-09-25 癌を処置するために使用されるｉｌ－１５融合ペプチド

Country Status (9)

Country Link
US (1) US20220372097A1 (enExample)
EP (1) EP4034552A1 (enExample)
JP (1) JP2023502843A (enExample)
CN (1) CN114651014A (enExample)
AU (1) AU2020351698A1 (enExample)
CA (1) CA3155100A1 (enExample)
GB (1) GB201913804D0 (enExample)
IL (1) IL291560A (enExample)
WO (1) WO2021058973A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502258A (ja) * 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019126240A1 (en) * 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
US20190263877A1 (en) * 2018-02-28 2019-08-29 Pfizer Inc. IL-15 Variants and Uses Thereof
WO2019166617A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502258A (ja) * 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019126240A1 (en) * 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
US20190263877A1 (en) * 2018-02-28 2019-08-29 Pfizer Inc. IL-15 Variants and Uses Thereof
WO2019166617A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15

Also Published As

Publication number Publication date
AU2020351698A1 (en) 2022-03-31
US20220372097A1 (en) 2022-11-24
EP4034552A1 (en) 2022-08-03
CN114651014A (zh) 2022-06-21
IL291560A (en) 2022-05-01
CA3155100A1 (en) 2021-04-01
WO2021058973A1 (en) 2021-04-01
GB201913804D0 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
CN102159708B (zh) 包含具有非常规生物活性的甘氨酰-tRNA合成酶的组合物和方法
KR102275008B1 (ko) 전립선 특이 막 항원 결합 단백질
KR100891272B1 (ko) 아폽토시스-촉진 단백질을 포함하는 치료제
JP2021506849A (ja) 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
JP2018076333A (ja) コンドロイチン硫酸グリカンのターゲティング
AU2012251919B2 (en) Compositions for regulating iron homeostasis and methods of using same
KR20180050679A (ko) 통증 치료용 조성물 및 방법
CN105209054A (zh) 使用白细胞介素-10治疗疾病和病症的方法
CN111093688A (zh) 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
JP2021506769A (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
TW201825122A (zh) 用精胺酸耗盡劑進行之組合癌症免疫療法
TWI396550B (zh) 在生理條件下具升高酵素活性的人類β－葡萄糖醛酸酶突變物及識別該酶之方法
JP2023502843A (ja) 癌を処置するために使用されるｉｌ－１５融合ペプチド
Zhang et al. The anticancer effect of PASylated calreticulin-targeting L-ASNase in solid tumor bearing mice with immunogenic cell death-inducing chemotherapy
JP6218175B2 (ja) ヘルパーｔ細胞誘導性ポリペプチドの改変
US20230181719A1 (en) Ngr conjugates and uses thereof
TW201902935A (zh) 蛋白質結合物
WO2014194428A1 (en) Targeted heparan sulfatase compounds
JP7701276B2 (ja) 併用療法
EP3828268A1 (en) Fragmented grs polypeptide and variant thereof, and use thereof
WO2024201004A1 (en) Combinatorial il-15 therapy
US20240100133A1 (en) Enzymatically inactive granzyme a and uses therefore
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
Zhu et al. An uPA cleavable conjugate of a recombinant αvβ3 targeting toxin and its bioactivity
CA3111216A1 (en) Peptide therapeutics for the treatment of cancer and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311